Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.60 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451815 | 0.85 | KMT2A (0.54) | L3MBTL1MEN1KMT2APRMT5WDR77 | |
| SCHEMBL5476399 | 0.76 | NPC1 (0.67) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL7816504 | 0.76 | NPC1 (0.71) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL7931528 | 0.76 | NPC1 (0.67) | L3MBTL1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL20887168 | 0.76 | RAB9A (0.71) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL4665324 | 0.73 | MEN1 (0.64) | L3MBTL1MEN1KMT2APRMT5WDR77 | |
| SCHEMBL5451682 | 0.73 | ALDH1A1 (0.64) | L3MBTL1MEN1KMT2ATAAR1MAPT | |
| SCHEMBL1156914 | 0.72 | NPC1 (0.74) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL1567603 | 0.72 | RAB9A (0.74) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL144325 | 0.71 | NPC1 (1.00) | KDM4EALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | L3MBTL1 4144/4885MEN1 2444/4885KMT2A 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.